The Garvan Institute of Medical Research and Cancer Therapeutics CRC Pty Ltd., of Melbourne, Australia, signed a license agreement with SYNkinase Pty Ltd., also of Melbourne, to develop and market a pan-kinase binding agent to help screen human cells and tissues and to identify potential drug targets in diseased states...In the coming months, the parties will enter license agreements for each aeroallergen, defining the opt-in terms for development and commercialization

In 2009, Regeneron Pharmaceuticals Inc., of Tarrytown, N.Y., updated its license agreement with Novartis related to canakinumab and a second antibody program using Regeneron's interleukin-1 Trap technology

Unigene Laboratories Inc., of Boonton, N.J., said it entered an equity transfer and exclusive license agreement with Nordic Bioscience A/S, of Herlev, Denmark, involving three metabolic peptide analogues for Type II diabetes, osteoarthritis and osteoporosis, developed as part of a joint development vehicle (JDV) established by both firms in October 2011

In other news, Addex said dipraglurant demonstrated dose-dependent mGlu5 receptor occupancy in a nonhuman primate positron emission tomography study, showing the correlation between the plasma concentration of dipraglurant and occupancy of dipraglurant on mGlu5 receptors in the brain...The goal is to validate emerging epigenetic targets for oncology indications and to demonstrate the eligibility of selected target families for drug formalations

Raptor's license agreement is with the Technology Transfer Accelerator of South Eastern France, which represents the French medical research organizations where the technology was invented

Ltd., of Osaka, Japan, entered a collaboration and license agreement to develop and market Allegro's Integrin Peptide Therapy in Japan...Under the license agreement, which covers lixisenatide and combination products, Zealand is entitled to tiered low double-digit percentage royalties on global net sales of Lyxumia and fixed low double-digit percentage royalties on full net sales of combination products including lixisenatide

Bial SA, of S. Mamede do Coronado, Portugal, signed an exclusive license agreement with Ono Pharmaceutical Co

Ltd., of Osaka, Japan, said they entered a license agreement providing Maruishi exclusive rights to develop, manufacture and commercialize Cara's lead analgesic drug candidate, CR845, for acute pain and uremic pruritus in Japan...Emisphere Technologies Inc., of Roseland, N.J., said it has agreed with Novo Nordisk A/S, of Bagsvaerd, Denmark, to amend their development and license agreement to develop and commercialize oral formulations of Novo Nordisk's GLP-1 receptor agonists, which have the

The companies previously inked a license agreement for the development and commercialization of the oral kinase inhibitor and, after generating positive preclinical data, Debiopharm decided to support Ascepion for further development in China, as the drug is designed to treat certain types of cancers that are highly prevalent in that country

Bial SA, of S. Mamede do Coronado, Portugal, signed an exclusive license agreement with Ono Pharmaceutical Co

Paragon BioTeck Inc., of Tigard, Ore., and Bausch + Lomb, of Madison, N.J., entered a license agreement to commercialize and distribute Paragon's phenylephrine in the U.S

BioTime Inc., of Alameda, Calif., entered an exclusive license agreement with the University of California, Los Angeles for technology related to the treatment of stroke

The companies previously inked a license agreement for the development and commercialization of the oral kinase inhibitor and, after generating positive preclinical data, Debiopharm decided to support Ascepion for further development in China, as the drug is designed to treat certain types of cancers that are highly prevalent in that country

Stem Cell Therapeutics Corp., of Toronto, said it executed a license agreement with University Health Network (UHN), developed in collaboration with MaRS Innovation, providing the company with exclusive worldwide rights to a clinical cancer stem cell program

Xencor Inc., of Monrovia, Calif., and CSL Ltd., of Parkville, Australia, signed a license agreement for Xencor to provide CSL with access to its Xtend technology for optimizing monoclonal antibodies

Ltd., of Osaka, Japan, entered a fourth amendment to their Feb. 13, 2006, and June 27, 2006, collaboration and license agreement for Omontys (peginesatide

Quest PharmaTech Inc., of Edmonton, Alberta, signed an exclusive license agreement with University of California at Los Angeles to develop and market anti-PSA IgE technology for the treatment of cancer

Ltd., of Seongnam, South Korea, executed a license agreement for two drug candidates, THVD-201 and THVD-202, granting SK Chemicals exclusive rights to develop and commercialize the compounds for overactive bladder and urge urinary incontinence

MaxCyte has an ongoing exclusive license agreement for Medinet Co